- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05230537
En maskert, placebokontrollert studie for å vurdere Iptacopan i aldersrelatert makuladegenerasjon
En randomisert, deltaker og etterforsker maskert, placebokontrollert, multisenter, bevis-av-konsept-studie for å vurdere sikkerheten og effekten av LNP023 (Iptacopan) hos pasienter med tidlig og middels aldersrelatert makuladegenerasjon
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This is a multicenter, randomized, participant and investigator masked, placebo controlled, proof-of-concept study to assess the safety and efficacy of Iptacopan (LNP023) in participants with early to intermediate age-related macular degeneration in one eye and neovascular age-related macular degeneration in the other eye. All enrolled participants must have early/intermediate AMD in one eye, with at least one high risk optical coherence tomography (OCT) feature (study eye) and neovascular AMD in the other eye (fellow eye).
Participants who meet all of the eligibility criteria will be randomized at the Baseline/Day 1 visit in a 1:1 ratio into one of two treatment arms:
- Iptacopan (LNP023) oral capsules
- Placebo oral capsules Approximately 146 participants (73 per arm) will be treated worldwide.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
California
-
Fullerton, California, Forente stater, 92835
- Retina Consultants of Orange County
-
Huntington Beach, California, Forente stater, 92647
- Salehi Retina Institute
-
Rancho Cordova, California, Forente stater, 95670
- Martel Eye Medical Group
-
Sacramento, California, Forente stater, 95841
- Retinal Consultants Medical Group Inc
-
Santa Barbara, California, Forente stater, 93103
- California Retina Consultants
-
-
Colorado
-
Durango, Colorado, Forente stater, 81303
- Southwest Retina Research Center
-
-
Florida
-
Deerfield Beach, Florida, Forente stater, 33064
- Advanced Research LLC
-
Delray Beach, Florida, Forente stater, 33484
- Retina Center Of South Florida
-
St. Petersburg, Florida, Forente stater, 33711
- Retina Vitreous Associates of Florida
-
-
Indiana
-
Carmel, Indiana, Forente stater, 46032
- Midwest Eye Institute
-
-
Louisiana
-
Metairie, Louisiana, Forente stater, 70001
- Retina Associates New Orleans
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21209
- Retina Care Center
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Opthamalic Consultants of Boston
-
-
New Jersey
-
Bloomfield, New Jersey, Forente stater, 07003
- Envision Ocular LLC
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27705
- Duke Eye Center
-
-
Oregon
-
Portland, Oregon, Forente stater, 97210
- Retina Northwest PC
-
-
Tennessee
-
Germantown, Tennessee, Forente stater, 38138
- Charles Retina Institute
-
-
Texas
-
Austin, Texas, Forente stater, 78793
- Austin Research Center for Retina
-
Bellaire, Texas, Forente stater, 77401
- Retina Consultants TX Rsrch Ctr
-
Dallas, Texas, Forente stater, 75231
- Retina Foundation
-
Fort Worth, Texas, Forente stater, 76104
- Texas Retina Associates
-
Houston, Texas, Forente stater, 77030
- Retina Consultants of Houston PA
-
-
-
-
-
Shanghai, Kina, 200080
- Novartis Investigative Site
-
-
Heilongjiang
-
Harbin, Heilongjiang, Kina, 150001
- Novartis Investigative Site
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 300020
- Novartis Investigative Site
-
-
-
-
-
Arecibo, Puerto Rico, 00612
- Emanuelli Research and Development Center LLC
-
-
-
-
-
London, Storbritannia, SE5 9RS
- Novartis Investigative Site
-
Southampton, Storbritannia, SO16 6YD
- Novartis Investigative Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male or female participants ≥ 50 years of age
- Diagnosis of early or intermediate age-related macular degeneration (AMD) in the study eye as determined by the investigator on fundus examination
- Study eye (early/intermediate AMD eye) must have at least one high risk optical coherence tomography (OCT) feature (as defined by a central reading center).
- Diagnosis of neovascular AMD (nAMD) in the fellow eye as determined by the investigator.
- Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection are required prior to the start of the treatment with LNP023.
- If not received previously, vaccination against Haemophilius influenzae infection should be given, if available and according to local regulations.
Exclusion Criteria:
- History or current diagnosis of ECG abnormalities indicating significant safety risk, such as clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia and clinically significant second or third degree atrioventricular block (AV block) without a pacemaker.
- History of familial long QT syndrome or known family history of Torsades de Pointes
- History of stroke or myocardial infarction during the 6-month period prior to Baseline/Day 1, any current clinically significant arrhythmias, or any advanced cardiac or severe pulmonary hypertension
- History of end stage kidney disease requiring dialysis or renal transplant
- History of malignancy of any organ system
- History of solid organ or bone marrow transplantation
- History of recurrent meningitis or history of meningococcal infections despite vaccination
- History of immunodeficiency diseases, including a positive Human Immunodeficiency Virus test result at Screening
- Active Hepatitis B (HBV) or Hepatitis C (HCV) infection
- History of hypersensitivity to any of the study treatments or excipients or to drugs of similar chemical classes or clinically relevant sensitivity to fluorescein dye as assessed by the Investigator.
- Evidence of cRORA or exMNV in the study eye based on multimodal imaging as determined by the central reading center.
- Participants who have current active TB as evidenced by clinical, radiographic and laboratory tests.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Iptacopan (LNP023)
Iptacopan (LNP023) oral use capsules |
oral capsules |
|
Placebo komparator: Placebo
Placebo matched to study drug, oral use capsules |
oral capsules |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Development of new incomplete retinal pigment epithelium & outer retinal atrophy or late age-related macular degeneration (AMD) in the early/intermediate AMD eye as determined by optical coherence tomography (OCT) & supported by multimodal imaging
Tidsramme: Baseline/Day 1 through Month 24
|
OCT and other imaging will be performed using spectral domain OCT or swept source OCT machines |
Baseline/Day 1 through Month 24
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The incidence of ocular and non-ocular adverse events (AEs)
Tidsramme: Baseline/Day 1 through Month 24
|
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. |
Baseline/Day 1 through Month 24
|
|
Change in Early Treatment Diabetic Retinopathy Study (ETDRS) (Standard Luminance) best corrected visual acuity (BCVA) scores in the early/intermediate AMD eye
Tidsramme: Baseline/Day 1 through Month 24
|
Best corrected visual acuity (BCVA) will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. The number of letters read correctly, for each eye, will be recorded. Participants at sites in some countries may conduct BCVA testing using numerical charts rather than letter charts. |
Baseline/Day 1 through Month 24
|
|
Change in ETDRS low luminance visual acuity (LLVA) scores in the early/intermediate AMD eye
Tidsramme: Baseline/Day 1 through Month 24
|
ETDRS low luminance visual acuity (LLVA) scores will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. The number of letters read correctly, for each eye, will be recorded. Participants at sites in some countries may conduct BCVA testing using numerical charts rather than letter charts. |
Baseline/Day 1 through Month 24
|
|
Change in contrast sensitivity (CS) scores in the early/intermediate AMD eye
Tidsramme: Baseline/Day 1 through Month 24
|
Pelli-Robson contrast sensitivity measurements will be performed using a Pelli-Robson contrast sensitivity wall chart and recording the number of correct letters read. |
Baseline/Day 1 through Month 24
|
|
Change in Standard luminance manifold contrast vision meter contrast sensitivity (MCVM-CS) scores in the early/intermediate AMD eye
Tidsramme: Baseline/Day 1 through Month 24
|
MCVM contrast sensitivity measurements will be performed using an automated device that uses an adaptive algorithm to rapidly measure a contrast sensitivity function in 5-10 minutes. |
Baseline/Day 1 through Month 24
|
|
Pharmacokinetics - concentrations of LNP023 related to trough samples
Tidsramme: Baseline/Day 1 through Month 24
|
Bioanalytical determination of plasma LNP023 concentrations related to trough samples using a LC-MS (mass spectrometry) method. |
Baseline/Day 1 through Month 24
|
|
Change in low luminance manifold contrast vision meter (MCVM) contrast sensitivity scores in the early/intermediate AMD eye
Tidsramme: Baseline/Day 1 through Month 24
|
MCVM contrast sensitivity measurements will be performed using an automated device that uses an adaptive algorithm to rapidly measure a contrast sensitivity function in 5-10 minutes. |
Baseline/Day 1 through Month 24
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CLNP023E12201
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .